Who are Placebo-Cetirizine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fexofenadine HCl, Hydroxyzine HCL, Morphine-Promethazine, Benadryl demand, alcaftadine 0.25% ophthalmic solution, olopatadine (OLO).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-cetirizine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo-Cetirizine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo-Cetirizine (Placebo-Cetirizine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective H1-receptor antagonist (second-generation antihistamine). Area: Immunology / Allergy.

phase 3 Selective H1-receptor antagonist (second-generation antihistamine) H1 histamine receptor Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Placebo-Cetirizine (Placebo-Cetirizine) — UCB Pharma. Cetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the central and peripheral nervous systems.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo-Cetirizine TARGET	Placebo-Cetirizine	UCB Pharma	phase 3	Selective H1-receptor antagonist (second-generation antihistamine)	H1 histamine receptor
fexofenadine HCl	fexofenadine HCl	Sanofi	marketed	Second-generation H1-receptor antagonist (non-sedating antihistamine)	H1 histamine receptor
Hydroxyzine HCL	Hydroxyzine HCL	National Cancer Institute (NCI)	marketed	First-generation H1 antihistamine	H1 histamine receptor
Morphine-Promethazine	Morphine-Promethazine	Tel-Aviv Sourasky Medical Center	marketed	Opioid analgesic combination	Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
Benadryl demand	Benadryl demand	University of Pennsylvania	marketed	First-generation H1 antihistamine	H1 histamine receptor
alcaftadine 0.25% ophthalmic solution	alcaftadine 0.25% ophthalmic solution	Allergan	marketed	Selective H1-receptor antagonist	H1 histamine receptor
olopatadine (OLO)	olopatadine (OLO)	University of Chicago	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective H1-receptor antagonist (second-generation antihistamine) class)

Organon and Co · 1 drug in this class
Sanofi · 1 drug in this class
UCB Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo-Cetirizine — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-cetirizine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab